Sugi Predict

Sugi Predict / Targets / PSMA2

PSMA2

Proteasome subunit alpha type-2 · P25787 · PSMA2 on Sugi Atlas →

23,593 patent compounds predicted against PSMA2, 16,184 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20

Clinical trials — most relevant to PSMA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy PHASE4RECRUITING
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function PHASE2ACTIVE_NOT_RECRUITING
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer PHASE2COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer PHASE1/PHASE2COMPLETED
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC PHASE1/PHASE2WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
PET/MRI to Stage Prostate Cancer Patients PHASE2RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: PHASE2ACTIVE_NOT_RECRUITING
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT PHASE1/PHASE2ACTIVE_NOT_RECRUITING
PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study PHASE2COMPLETED
Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection PHASE2RECRUITING
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 PHASE1COMPLETED
The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma PHASE1RECRUITING
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT EARLY_PHASE1RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 nanCOMPLETED
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients nanNOT_YET_RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas nanCOMPLETED
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient nanRECRUITING
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer. nanSUSPENDED

Related proteins — ESM-2 sequence neighbours (a PSMA2 binder may also engage these)

ProteinNameSimilarity
O73672 — 1.000 O73672 →
P17220 — 1.000 P17220 →
P49722 — 1.000 P49722 →
P40301 — 1.000 P40301 →
Q8L4A7 — 1.000 Q8L4A7 →
Q10KF0 — 1.000 Q10KF0 →
Q27488 — 1.000 Q27488 →
Q3T0Y5 — 1.000 Q3T0Y5 →
C3NHC6 — 1.000 C3NHC6 →
C4KHD9 — 1.000 C4KHD9 →
Q8TPX5 — 1.000 Q8TPX5 →
P34064 — 1.000 P34064 →
A7I9C7 — 0.999 A7I9C7 →
O23708 — 0.999 O23708 →
Q4JB24 — 0.999 Q4JB24 →
Q8X077 — 0.999 Q8X077 →
O16812 — 0.999 O16812 →
C3N5R0 — 0.999 C3N5R0 →
Q3T0X5 — 0.999 Q3T0X5 →
Q59565 — 0.998 Q59565 →
P90513 — 0.998 P90513 →
O13268 — 0.998 O13268 →
A4YCU9 — 0.998 A4YCU9 →
A2YVR7 — 0.998 A2YVR7 →
Q9R1P0 — 0.998 Q9R1P0 →
C3NEC6 — 0.997 C3NEC6 →
C3MQ43 — 0.997 C3MQ43 →
PSMA1 Proteasome subunit alpha type-1 0.997 landscape →
P24495 — 0.997 P24495 →
Q54DM7 — 0.997 Q54DM7 →